Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
FesariusTherapeutics
AddedFeb 16, 2024
UpdatedJun 18, 2026
FesariusTherapeutics

FesariusTherapeutics

Pre-Seed

Fesarius Therapeutics: A biotech firm innovating affordable skin replacement products for trauma and burn healing.

HQ
New York City, NY, US
Founded
2015
Overview
Compare
Fundraising
Employees
Website

Fesarius Therapeutics, founded with the mission to innovate affordable skin replacement products, focuses on developing advanced tissue engineering solutions for trauma and burn healing. The company utilizes a proprietary technique involving microsphere-containing hydrogels embedded in collagen to enhance cell invasion and scaffold integration. Their flagship product, DermiSphere™, aims to revolutionize the treatment of full-thickness skin loss, providing an effective and accessible option for patients recovering from severe skin injuries.

Notable figures affiliated with Fesarius Therapeutics include leading experts in biotechnology and tissue engineering. The company has garnered attention from prominent investors in the biotech sector, contributing to its rapid development and market entry. Key achievements include the successful development and preliminary testing of DermiSphere™, positioning Fesarius Therapeutics as a significant player in the field of regenerative medicine. The overall impact of their innovations promises to improve recovery outcomes for patients suffering from severe skin damage.

FesariusTherapeutics - Similar Companies

DermBiont logo

DermBiont

dermbiont.com

Fount Bio logo

Fount Bio

fountbio.com

Thesan Pharmaceuticals logo

Thesan Pharmaceuticals

thesanpharma.com

FibRx Derm logo

FibRx Derm

MatriSys Bioscience logo

MatriSys Bioscience

matrisysbio.com

Dermaliq Therapeutics logo

Dermaliq Therapeutics

dermaliq.com

SironRX Therapeutics logo

SironRX Therapeutics

sironrx.com

Lotus Tissue Repair logo

Lotus Tissue Repair

NovoThelium logo

NovoThelium

novothelium.com

inSoma Bio logo

inSoma Bio

insomabio.com

LifeSprout logo

LifeSprout

lifesproutbio.com

Amphix Bio logo

Amphix Bio

amphixbio.com

Spheringenics logo

Spheringenics

Forkhead BioTherapeutics logo

Forkhead BioTherapeutics

forkheadbio.com

Microdermis logo

Microdermis

FesariusTherapeutics - Quick Facts

Who are FesariusTherapeutics' competitors?

Companies similar to FesariusTherapeutics include DermBiont, Fount Bio, Thesan Pharmaceuticals and FibRx Derm.

When was FesariusTherapeutics founded?

FesariusTherapeutics was founded in 2015.

Where is FesariusTherapeutics' headquarters located?

FesariusTherapeutics' headquarters is located in New York City, NY, US.

When was FesariusTherapeutics' last funding round?

FesariusTherapeutics' most recent funding round was for $800k (USD) in August 2023.

How much has FesariusTherapeutics raised to-date?

As of Aug 16, 2023, FesariusTherapeutics has raised a total of $2.6M (USD).

How many employees does FesariusTherapeutics have?

FesariusTherapeutics has 7 employees as of Feb 4, 2024.

FesariusTherapeutics - Classification

Industry
  • Hardware
Ownership
  • Venture Capital
Technology
  • Biotech
Geographic Exposure
  • Americas
Revenue
  • Transactional
Customer
  • Enterprise
Main Product
  • Skin Replacement
Tags
  • Healthcare
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 15 more industry codes
NAICS
  • 513200Software Publishers
  • 541714Research and Development in Biotechnology (except Nanobiotechnology)
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 541700Scientific Research and Development Services
  • 513210Software Publishers
  • 541710Research and Development in the Physical, Engineering, and Life Sciences
SIC
  • 8000Health Services
  • 8700Engineering, Accounting, Research, Management, And Related Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 8730Research, Development, And Testing Services
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified
  • 8731Commercial Physical and Biological Research